Cerity Partners LLC Sells 39,420 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cerity Partners LLC decreased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 31.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,651 shares of the company's stock after selling 39,420 shares during the period. Cerity Partners LLC's holdings in Takeda Pharmaceutical were worth $1,204,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $26,000. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical during the 3rd quarter worth $40,000. BNP Paribas Financial Markets boosted its position in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after buying an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $52,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Down 0.2 %

Shares of TAK traded down $0.04 on Thursday, reaching $15.15. 662,348 shares of the company's stock were exchanged, compared to its average volume of 1,942,862. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.37. The stock has a market capitalization of $48.19 billion, a P/E ratio of 37.86, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $14.67 and a two-hundred day moving average price of $13.93.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.